Loading...

Sintx Technologies

Nasdaq:SINT
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SINT
Nasdaq
$5M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America. The last earnings update was 46 days ago. More info.


Add to Portfolio Compare Print
  • Sintx Technologies has significant price volatility in the past 3 months.
SINT Share Price and Events
7 Day Returns
9.9%
NasdaqCM:SINT
-1.6%
US Medical Equipment
0.9%
US Market
1 Year Returns
-80.9%
NasdaqCM:SINT
15.6%
US Medical Equipment
9.6%
US Market
SINT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sintx Technologies (SINT) 9.9% 9.9% 5.3% -80.9% -98.8% -100%
US Medical Equipment -1.6% -4.3% 4.1% 15.6% 51.6% 93.5%
US Market 0.9% 4.6% 10.9% 9.6% 39% 47.2%
1 Year Return vs Industry and Market
  • SINT underperformed the Medical Equipment industry which returned 15.6% over the past year.
  • SINT underperformed the Market in United States of America which returned 9.6% over the past year.
Price Volatility
SINT
Industry
5yr Volatility vs Market

SINT Value

 Is Sintx Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sintx Technologies. This is due to cash flow or dividend data being unavailable. The share price is $0.22.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sintx Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sintx Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:SINT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.16
NasdaqCM:SINT Share Price ** NasdaqCM (2019-04-25) in USD $0.22
United States of America Medical Equipment Industry PE Ratio Median Figure of 63 Publicly-Listed Medical Equipment Companies 39.57x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 18.28x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sintx Technologies.

NasdaqCM:SINT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:SINT Share Price ÷ EPS (both in USD)

= 0.22 ÷ -2.16

-0.1x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sintx Technologies is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Sintx Technologies is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Sintx Technologies's expected growth come at a high price?
Raw Data
NasdaqCM:SINT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.1x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Medical Equipment Industry PEG Ratio Median Figure of 54 Publicly-Listed Medical Equipment Companies 2.35x
United States of America Market PEG Ratio Median Figure of 2,113 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sintx Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sintx Technologies's assets?
Raw Data
NasdaqCM:SINT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.39
NasdaqCM:SINT Share Price * NasdaqCM (2019-04-25) in USD $0.22
United States of America Medical Equipment Industry PB Ratio Median Figure of 184 Publicly-Listed Medical Equipment Companies 4.25x
United States of America Market PB Ratio Median Figure of 5,185 Publicly-Listed Companies 1.92x
NasdaqCM:SINT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:SINT Share Price ÷ Book Value per Share (both in USD)

= 0.22 ÷ 0.39

0.57x

* Primary Listing of Sintx Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sintx Technologies is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Sintx Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Sintx Technologies has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SINT Future Performance

 How is Sintx Technologies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sintx Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.8%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sintx Technologies expected to grow at an attractive rate?
  • Unable to compare Sintx Technologies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Sintx Technologies's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Sintx Technologies's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:SINT Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 20.8%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:SINT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:SINT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
NasdaqCM:SINT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -9 -24
2018-09-30 11 -8 -29
2018-06-30 10 -7 -20
2018-03-31 11 -5 -12
2017-12-31 -5 -6
2017-09-30 4 -6 -5
2017-06-30 13 -8 -15
2017-03-31 14 -8 -18
2016-12-31 15 -7 -21
2016-09-30 17 -7 -22
2016-06-30 18 -6 -21
2016-03-31 19 -8 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Sintx Technologies is high growth as no earnings estimate data is available.
  • Unable to determine if Sintx Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:SINT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Sintx Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:SINT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
NasdaqCM:SINT Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.16
2018-09-30 -4.65
2018-06-30 -5.25
2018-03-31 -3.91
2017-12-31 -1.93
2017-09-30 -1.78
2017-06-30 -5.91
2017-03-31 -9.01
2016-12-31 -13.63
2016-09-30 -19.72
2016-06-30 -28.14
2016-03-31 -39.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sintx Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Sintx Technologies's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Sintx Technologies's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Sintx Technologies's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Sintx Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sintx Technologies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SINT Past Performance

  How has Sintx Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sintx Technologies's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sintx Technologies does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Sintx Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sintx Technologies's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Sintx Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sintx Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:SINT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.10 -23.59 4.00 2.99
2018-09-30 11.23 -29.17 11.26 4.43
2018-06-30 9.72 -20.16 10.14 5.27
2018-03-31 10.89 -12.23 10.77 5.30
2017-12-31 -5.76 3.98 3.51
2017-09-30 3.65 -4.90 6.54 4.23
2017-06-30 12.87 -14.80 13.45 5.54
2017-03-31 13.68 -18.17 14.54 5.75
2016-12-31 15.23 -21.04 15.94 6.35
2016-09-30 16.67 -22.38 17.04 6.06
2016-06-30 18.13 -21.05 17.12 6.15
2016-03-31 18.88 -21.92 17.63 6.15
2015-12-31 19.45 -23.91 18.86 6.39
2015-09-30 19.51 -31.15 19.31 6.21
2015-06-30 20.67 -25.94 22.71 6.51
2015-03-31 21.73 -33.25 30.07 7.99
2014-12-31 22.77 -32.58 32.28 6.74
2014-09-30 23.32 -22.22 33.10 6.20
2014-06-30 22.62 -19.64 30.28 4.89
2014-03-31 22.84 -9.47 24.72 3.00
2013-12-31 22.31 -8.29 22.14 3.46
2013-09-30 22.54 -33.27 23.20 4.39
2013-06-30 22.95 -33.60 24.29 5.09
2013-03-31 22.61 -34.55 23.73 5.50
2012-12-31 23.07 -35.04 24.41 6.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sintx Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sintx Technologies has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sintx Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sintx Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sintx Technologies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SINT Health

 How is Sintx Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sintx Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sintx Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sintx Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sintx Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Sintx Technologies has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sintx Technologies Company Filings, last reported 3 months ago.

NasdaqCM:SINT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 8.40 0.00 5.45
2018-09-30 8.09 0.00 6.79
2018-06-30 11.31 2.48 8.84
2018-03-31 5.99 4.51 0.41
2017-12-31 5.44 0.61 0.54
2017-09-30 10.44 4.61 2.82
2017-06-30 12.27 3.97 3.46
2017-03-31 13.91 5.48 6.94
2016-12-31 11.24 7.01 6.92
2016-09-30 11.50 8.48 10.61
2016-06-30 9.75 11.21 5.16
2016-03-31 10.93 14.79 7.94
2015-12-31 14.23 16.37 11.49
2015-09-30 -1.72 19.97 11.27
2015-06-30 8.16 22.55 12.39
2015-03-31 3.18 22.27 14.88
2014-12-31 6.91 22.13 18.25
2014-09-30 11.96 22.70 10.36
2014-06-30 14.86 20.12 11.55
2014-03-31 20.46 16.13 13.26
2013-12-31 8.41 17.93 2.28
2013-09-30 8.01 17.92 7.56
2013-06-30 2.31 19.18 2.75
2013-03-31 5.72 20.47 5.42
2012-12-31 5.72 20.47 5.42
  • Sintx Technologies has no debt.
  • Sintx Technologies has no debt compared to 5 years ago when it was 209.7%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sintx Technologies has less than a year of cash runway based on current free cash flow.
  • Sintx Technologies has less than a year of cash runway if free cash flow continues to reduce at historical rates of -2.1% each year.
X
Financial health checks
We assess Sintx Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sintx Technologies has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SINT Dividends

 What is Sintx Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sintx Technologies dividends.
If you bought $2,000 of Sintx Technologies shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sintx Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sintx Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:SINT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:SINT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sintx Technologies has not reported any payouts.
  • Unable to verify if Sintx Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sintx Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sintx Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sintx Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sintx Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sintx Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SINT Management

 What is the CEO of Sintx Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
B. Bal
COMPENSATION $411,693
AGE 56
TENURE AS CEO 4.5 years
CEO Bio

Dr. B. Sonny Bal, M.D., J.D., MBA, PhD, has been the Chief Executive Officer and President of Sintx Technologies, Inc. (formerly known as Amedica Corporation) since October 2014 and its Chairman since August 21, 2014. Dr. Bal serves as Principal Financial Officer at Sintx Technologies, Inc. (formerly known as Amedica Corporation). Dr. Bal serves as an Assistant Professor of Orthopaedic Surgery at the University of Missouri, Columbia, specializing in hip and knee replacement surgery. Dr. Bal is Professor & Chief of Adult Reconstruction at the University of Missouri, Columbia. He also is an Adjunct Professor of Material Sciences at the University of Missouri at Rolla. Dr. Bal has been a Director of Sintx Technologies, Inc. (formerly known as Amedica Corporation) since February 8, 2012. Dr. Bal received his M.D. degree from Cornell University and an M.B.A. from Northwestern University, a J.D. from the University of Missouri, a Ph.D. in Engineering from the Kyoto Institute of Technology in Japan and is a member of the American Academy of Orthopaedic Surgeons and the American Association of Hip and Knee Surgeons and the International Society of Technology in Arthroplasty. Dr. Bal is a licensed attorney and co-founder of the Bal Brenner law firm in North Carolina.

CEO Compensation
  • B.'s compensation has been consistent with company performance over the past year.
  • B.'s remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure of the Sintx Technologies management team in years:

3.9
Average Tenure
  • The tenure for the Sintx Technologies management team is about average.
Management Team

B. Bal

TITLE
Chairman
COMPENSATION
$412K
AGE
56
TENURE
4.5 yrs

Bryan McEntire

TITLE
Chief Scientific Officer
COMPENSATION
$244K
AGE
66
TENURE
1.3 yrs

David O'brien

TITLE
GM & VP Operations
TENURE
3.9 yrs
Board of Directors Tenure

Average tenure and age of the Sintx Technologies board of directors in years:

4.7
Average Tenure
58.5
Average Age
  • The tenure for the Sintx Technologies board of directors is about average.
Board of Directors

B. Bal

TITLE
Chairman
COMPENSATION
$412K
AGE
56
TENURE
4.7 yrs

Dave Truetzel

TITLE
Director
COMPENSATION
$124K
AGE
61
TENURE
8.6 yrs

Jeff White

TITLE
Director
COMPENSATION
$43K
AGE
64
TENURE
5.3 yrs

Eric Stookey

TITLE
Director
COMPENSATION
$44K
AGE
48
TENURE
4.5 yrs

Giuseppe Pezzotti

TITLE
Member of Scientific Advisory Board
TENURE
3.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Sintx Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sintx Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SINT News

Simply Wall St News

SINT Company Info

Description

Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America. The company offers ceramic based biomaterial solutions in various medical and industrial applications. It provides spine implant products under the Valeo brand to surgeons and hospitals for use in cervical and thoracolumbar spine surgery. The company markets and sells its products directly; and through direct sales organizations, distributors, as well as original equipment manufacturer and private label partnerships. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was founded in 1996 and is headquartered in Salt Lake City, Utah.

Details
Name: Sintx Technologies, Inc.
SINT
Exchange: NasdaqCM
Founded: 1996
$4,794,601
21,793,641
Website: http://www.sintx.com
Address: Sintx Technologies, Inc.
1885 West 2100 South,
Salt Lake City,
Utah, 84119,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM SINT Common Stock Nasdaq Capital Market US USD 14. Feb 2014
DB 111M Common Stock Deutsche Boerse AG DE EUR 14. Feb 2014
Number of employees
Current staff
Staff numbers
19
Sintx Technologies employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/26 02:20
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2018/03/29
Last earnings filing: 2019/03/11
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.